NASDAQ$BNGO
BioNano Genomics Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Reported financial results for the fourth quarter and full year ended December 31, 2021, with revenue increased and strategic acquisitions made.
Bionano Genomics reported a 58% increase in revenue for Q4 2021 compared to the same period in 2020, with a record revenue of $6.3 million. The company expanded its installed base of Saphyr systems and acquired BioDiscovery. The company ended the year with $250.6 million in cash, cash equivalents, and available-for-sale securities.
- Revenue for the fourth quarter of 2021 was $6.3 million, up 58% from the same period in 2020.
- Expanded the installed base of Saphyr systems from 141 at the end of Q3 to 164 at the end of Q4.
- Sold 3,204 nanochannel array flow cells during the quarter ended December 31, 2021, which represents 29% growth over the same quarter in 2020.
- Acquired BioDiscovery, Inc., including its industry-leading software, NxClinical, to accelerate and broaden Bionano’s position in digital cytogenetics and comprehensive genome analysis.
Headline financials
Revenue & EPS history
BioNano · Revenue · Quarterly
$6.3M
Revenue by segment
BioNano · $6.3M total across 2 segments · Q4 2021
- Product Revenue$3.85M+41.2%61.1%
- Service and Other Revenue$2.45M+94.1%38.9%
Forward guidance
Bionano expects full year 2022 revenue to be in the range of $24 million to $27 million, which would represent a range of 33% to 50% growth over full year 2021 revenue.
Tailwinds
- Receive IRB approval for hematological study in Q1 2022
- Apply for category 1 CPT code for OGM in Q1 2022
- Site selection complete and enrollment commencement for hematological malignancy study in Q2 2022
- Data generation commencement for prenatal study in Q2 2022
- Bionano Labs test menu expanded to include genetic disease and hematological malignancies in Q3 2022
Headwinds
- Completion of postnatal study (enrollment, analysis and assessment of all primary endpoints) in Q4 2022
- Release labeling protocol 2.0 and SP Next DNA isolation protocol in Q4 2022
- Pre-commercial version of new high throughput imaging system for OGM system running in the field in Q4 2022
- Interim publication on prenatal study in Q4 2022
- Installed base of 240 Saphyr systems in Q4 2022, which would represent at least a 45% growth from year-end 2021
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q4 2021
-3.3%
Avg return
Earnings day
-5.4%
Avg return
5 days after
-7.7%
Avg return
30 days after
40%
12 / 30 earnings
Positive
+15.5%
Q4 2018
Best reaction
-29.8%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +0.9% | +1.6% | — | |
| Q1 2026 | -0.8% | -9.5% | -7.9% | |
| Q3 2025 | +2.8% | +4.8% | +10.2% | |
| Q1 2025 | +2.9% | +0.8% | -2.4% | |
| Q4 2024 | +11.1% | +8.6% | +43.4% | |
| Q3 2024 | -3.4% | -11.5% | -7.7% | |
| Q2 2024 | -21.5% | -23.5% | -13.7% | |
| Q1 2024 | +2.7% | +7.3% | -9.4% | |
| Q4 2023 | +0.0% | -5.8% | -18.2% | |
| Q3 2023 | -7.0% | -10.5% | +2.8% | |
| Q2 2023 | -0.2% | -13.9% | -15.7% | |
| Q1 2023 | +6.9% | -9.6% | +0.0% | |
| Q4 2022 | -8.4% | -5.3% | -19.8% | |
| Q3 2022 | +2.7% | +2.2% | -6.3% | |
| Q2 2022 | +6.6% | +0.0% | +2.2% | |
| Q1 2022 | -16.1% | -24.2% | -10.8% | |
| Q4 2021 | +1.4% | -10.7% | +20.6% | |
| Q3 2021 | -9.8% | -13.7% | -44.4% | |
| Q2 2021 | +5.4% | +4.4% | -1.0% | |
| Q1 2021 | +13.9% | +22.8% | +59.9% | |
| Q4 2020 | -17.9% | -14.4% | -34.1% | |
| Q3 2020 | -7.4% | -5.4% | -10.7% | |
| Q2 2020 | -8.4% | -6.5% | -32.5% | |
| Q1 2020 | -8.4% | -11.8% | +21.6% | |
| Q4 2019 | -29.8% | -30.3% | -74.3% | |
| Q3 2019 | -2.1% | +17.8% | +24.4% | |
| Q2 2019 | -14.4% | -11.3% | -50.5% | |
| Q1 2019 | -11.3% | -17.0% | -28.1% | |
| Q4 2018 | +15.5% | +7.4% | -8.1% | |
| Q3 2018 | -6.0% | -5.7% | -11.9% | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro